TEVA Overzicht aandelen
Teva Pharmaceutical Industries Limited ontwikkelt, produceert, verkoopt en distribueert generieke geneesmiddelen, speciale geneesmiddelen en biofarmaceutische producten in Noord-Amerika, Europa, Israël en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 6/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor TEVA uit onze risicocontroles.
Teva Pharmaceutical Industries Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$17.12 |
| 52 Week Hoogtepunt | US$19.31 |
| 52 Week Laag | US$9.35 |
| Bèta | 0.87 |
| 11 maand verandering | -4.36% |
| 3 maanden verandering | -7.96% |
| 1 Jaar Verandering | 79.27% |
| 33 jaar verandering | 101.65% |
| 5 jaar verandering | 64.30% |
| Verandering sinds IPO | 4,114.15% |
Recent nieuws en updates
Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S
Nov 17
Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
Oct 23Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?
Oct 21Recent updates
Why Investors Shouldn't Be Surprised By Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Low P/S
Nov 17Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
Oct 23Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?
Oct 21Cheap Teva Stock Should Reward Patient Investors
Sep 09Teva's Transformation: From Generics Leader To Branded Drug Innovator
Aug 14Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 02Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Jul 26Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Jul 12Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
May 14Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Rendement voor aandeelhouders
| TEVA | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 4.2% | 1.6% | 2.2% |
| 1Y | 79.3% | 9.9% | 31.6% |
Rendement versus industrie: TEVA overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 9.9 % opleverde.
Rendement versus markt: TEVA overtrof de US markt, die het afgelopen jaar een rendement opleverde van 31.6 %.
Prijsvolatiliteit
| TEVA volatility | |
|---|---|
| TEVA Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: TEVA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van TEVA is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1901 | 37,000 | Richard Francis | www.tevapharm.com |
Teva Pharmaceutical Industries Limited ontwikkelt, produceert, verkoopt en distribueert generieke geneesmiddelen, speciale geneesmiddelen en biofarmaceutische producten in Noord-Amerika, Europa, Israël en internationaal. Het biedt generieke geneesmiddelen in verschillende doseringsvormen, zoals tabletten, capsules, injecteerbare middelen, inhaleermiddelen, vloeistoffen, transdermale pleisters, zalven en crèmes; steriele producten, hormonen, hoogpotente geneesmiddelen en cytotoxische stoffen in parenterale en vaste doseringsvormen; en generieke producten met medische hulpmiddelen en combinatieproducten. Het bedrijf richt zich op het centrale zenuwstelsel (CZS), de luchtwegen en oncologie.
Teva Pharmaceutical Industries Limited Samenvatting
| TEVA fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$19.40b |
| Inkomsten(TTM) | -US$959.00m |
| Inkomsten(TTM) | US$16.77b |
1.2x
P/S-verhouding-20.2x
Koers/WinstverhoudingIs TEVA overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| TEVA resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$16.77b |
| Kosten van inkomsten | US$8.41b |
| Brutowinst | US$8.36b |
| Overige uitgaven | US$9.32b |
| Inkomsten | -US$959.00m |
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.85 |
| Brutomarge | 49.84% |
| Nettowinstmarge | -5.72% |
| Schuld/Eigen Vermogen Verhouding | 297.3% |
Hoe presteerde TEVA op de lange termijn?
Bekijk historische prestaties en vergelijking